Biopharmaceutical company PolyPid Ltd. is scheduled to present new data from its Phase 3 SHIELD II clinical trial at the upcoming ESCMID Global 2026 congress. The presentation will focus on D-PLEX100, the company's investigational product designed for the sustained local release of antibiotics to prevent surgical site infections (SSIs) following abdominal surgery.
The SHIELD II trial is a pivotal study evaluating the efficacy and safety of D-PLEX100 in patients undergoing colorectal surgery. The primary endpoint is the reduction in the incidence of surgical site infections. PolyPid's technology aims to provide prolonged, localized antibiotic delivery directly at the surgical site over several weeks.
ESCMID Global (European Society of Clinical Microbiology and Infectious Diseases) is a major international conference for infectious disease specialists. The 2026 congress will be held in Madrid, Spain, from April 25-28. Presentations of late-breaking clinical trial data are a standard feature of the event's scientific program.
The presentation of this Phase 3 data is a significant step for PolyPid as it seeks regulatory approval for D-PLEX100. The company has previously reported topline results from the SHIELD II study, indicating it met its primary endpoint with statistical significance.
